

101.623-12 – including *Taq* pol., IFU-01
 101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
 “Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information
Olerup SSP[®] HLA-C*08

Product number:	101.623-12 – including <i>Taq</i> polymerase 101.623-12u – without <i>Taq</i> polymerase
Lot number:	1F2
Expiry date:	2019-10-01
Number of tests:	12
Number of wells per test:	40+1
Storage - pre-aliquoted primers:	dark at -20°C
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

This Product Description is only valid for Lot No. 1F2.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP[®]
 HLA-C*08 LOT (61Y)**

The HLA-C*08 kit is updated for new alleles to enable separation of:

- Confirmed¹ alleles as listed in the IMGT/HLA database
- Polymorphisms in exons outside of the region encoding the peptide binding domain
- Null and Alternatively expressed alleles

Nine wells have been added to HLA-C*08, wells **33 to 41**.

¹As described in section Uniquely Identified Alleles.

The HLA-C*08 primer set, specificity and interpretation tables have been updated for the HLA-C alleles described since the previous *Olerup SSP[®] HLA-C*08* lot was made (**Lot No. 61Y**). The kit design is based on IMGT/HLA database 3.26.0.

As of lot series V, the Specificity Table is included in the lot-specific Product Insert, and the Interpretation Table is included in the Worksheet.

101.623-12 – including *Taq* pol., IFU-01

101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
 “Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
5	-	Added	3'-primer added for increased yield.
11	Added	-	5'-primer added for the C*08:128 allele.
26	Moved	Moved	Primer pairs moved to well 40 for decreased tendency of primer oligomer formation.
28	Moved	Moved	Primer pair moved to well 32 for improved allelic resolution.
29	Added	-	5'-primer added for the C*08:128 allele.
32	Added	Added	Negative Control moved to well 41, primer pair added from well 28 for improved allelic resolution.
33	New	New	New primer pair added for improved allelic resolution of the C*08:15:01-08:15:02 and 08:51 alleles.
34	New	New	New primer pair added for improved allelic resolution of the B*08:55N and 08:94 alleles.
35	New	New	New primer pair added for the C*08:72:02 allele.
36	New	New	New primer pair added for the C*08:121N allele.
37	New	New	New primer pair added for the C*08:127N and C*08:141Q alleles.
38	New	New	New primer pair added for the C*08:129N and C*08:141Q alleles.
39	New	New	New primer pair added for the C*08:130 allele.
40	Added	Added	Primer pair added from well 26 for decreased tendency of primer oligomer formation.
41	Added	Added	Negative Control added from well 32.

101.623-12 – including *Taq* pol., IFU-01

101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

Well **41** contains Negative Control primer pairs, that will amplify more than 95% of the *Olerup SSP*[®] HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 430 base pairs.

Length of PCR product	105	200	105	80	75	80	85
5'-primer¹	164	340	440	45	45	43	36
	5'-CAC ^{3'}	5'-Agg ^{3'}	5'-TTA ^{3'}	5'-Tgg ^{3'}	5'-Tgg ^{3'}	5'-Tgg ^{3'}	5'-TAC ^{3'}
							36
							5'-TAT ^{3'}
3'-primer²	231	2nd I	507	59	58	57	47
	5'-TgC ^{3'}	5'-AAA ^{3'}	5'-TTg ^{3'}	5'-CTC ^{3'}	5'-ggC ^{3'}	5'-CTC ^{3'}	5'-ACA ^{3'}
							48
							5'-gCA ^{3'}
							48
							5'-gCC ^{3'}
							52
							5'-TgT ^{3'}
A*	+	+	+				
B*	+	+	+				
C*	+	+	+				
DRB1				+	+		
DRB3				+	+		
DRB5				+			
DQB1					+		
DPB1						+	
DQA1							+

¹The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

²The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon or the 2nd intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.623-12 – including *Taq* pol., IFU-01
101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information
PRODUCT DESCRIPTION

HLA-C*08 SSP typing

CONTENT

The primer set contains 5'- and 3'-primers for identifying the C*08:01 to C*08:143 alleles.

PLATE LAYOUT

Each HLA-C*08 test consists of 41 PCR reactions in a 48 well cut PCR plate. Wells 42 to 48 are empty.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	24
25	26	27	28	29	30	31	32
33	34	35	36	37	38	39	40
NC	empty	empty	empty	empty	empty	empty	empty

The 48 well PCR plate is marked with ‘HLA-C*08’ in silver/gray ink.

Well No. 1 is marked with the Lot No. ‘1F2’.

Wells 1 to 40 – HLA-C*08 high resolution primers.

Well 41 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded. The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 48 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

Due to the sharing of sequence motifs between HLA-C alleles non-HLA-C*08 alleles will be amplified by primer mixes 1 to 7, 9, 11 to 35 and 40 amplify non-HLA-C*08 alleles. In addition, a few HLA-A and HLA-B alleles will be amplified by primer mixes 1, 3, 5 to 7, 11, 14, 20, 22, 23, 25, 26, 30 to 33, 35 and 36.

For further details see Specificity Table.

UNIQUELY IDENTIFIED ALLELES

All the HLA-C*08 alleles, i.e. **C*08:01 to C*08:143**, recognized by the HLA Nomenclature Committee in October 2016¹ will be amplified by the primers in the HLA-C*08 SSP kit².

The HLA-C*08 kit enables separation of the confirmed HLA-C*08 alleles as listed in the IMGT/HLA database. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-C*08 alleles is listed below.

101.623-12 – including *Taq* pol., IFU-01

101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
 “Instructions for Use” (IFU)

Lot No.: 1F2

Lot-specific information

The HLA-C*08 kit also enables identification of polymorphisms in exons outside of the region encoding the peptide binding domain and of null and alternatively expressed alleles.

The HLA-C*08 primer set cannot distinguish the following silent mutations: the C*08:01:01-08:01:06 and C*08:01:08-08:01:19 alleles, the C*08:02:01:01-08:02:05 and C*08:02:08-08:02:14 alleles, the 08:03:01-08:03:04 alleles, the C*08:04:01-08:04:03 alleles, the C*08:08:01-08:08:02 alleles, the 08:15:01-08:15:02 alleles, the C*08:16:01-08:16:02 alleles or the C*08:72:01-08:72:02 alleles.

The following HLA-C*08 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix	Alleles	Primer mix
C*08:20, 08:99	30	C*08:36N, 08:78	23
C*08:24, 08:88N	9	C*08:69, 08:70Q	23
C*08:30, 08:32	19		

¹HLA-C alleles listed on the IMGT/HLA web page 2016-October-14, release 3.26.0, www.ebi.ac.uk/imgt/hla.

²Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

101.623-12 – including *Taq* pol., IFU-01
 101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
 “Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

ALLELE CONFIRMATION STATUS

Allele	Status ¹	Allele	Status ¹	Allele	Status ¹	Allele	Status ¹
C*08:01:01	Confirmed	C*08:13	Unconfirmed	C*08:59	Unconfirmed	C*08:109	Unconfirmed
C*08:01:02	Confirmed	C*08:14	Unconfirmed	C*08:60	Unconfirmed	C*08:110	Unconfirmed
C*08:01:03	Unconfirmed	C*08:15:01	Confirmed	C*08:61	Unconfirmed	C*08:111	Unconfirmed
C*08:01:04	Unconfirmed	C*08:15:02	Confirmed	C*08:62	Unconfirmed	C*08:112	Confirmed
C*08:01:05	Unconfirmed	C*08:16:01	Unconfirmed	C*08:63	Unconfirmed	C*08:113	Unconfirmed
C*08:01:06	Unconfirmed	C*08:16:02	Unconfirmed	C*08:65	Unconfirmed	C*08:114	Unconfirmed
C*08:01:07	Confirmed	C*08:17	Unconfirmed	C*08:66	Confirmed	C*08:115	Confirmed
C*08:01:08	Unconfirmed	C*08:18	Unconfirmed	C*08:67	Unconfirmed	C*08:116	Unconfirmed
C*08:01:09	Confirmed	C*08:19	Unconfirmed	C*08:68	Unconfirmed	C*08:117	Unconfirmed
C*08:01:10	Confirmed	C*08:20	Confirmed	C*08:69	Confirmed	C*08:118	Unconfirmed
C*08:01:11	Unconfirmed	C*08:21	Confirmed	C*08:70Q	Unconfirmed	C*08:119	Unconfirmed
C*08:01:12	Unconfirmed	C*08:22	Confirmed	C*08:71	Unconfirmed	C*08:120	Unconfirmed
C*08:01:13	Unconfirmed	C*08:23	Confirmed	C*08:72:01	Unconfirmed	C*08:121N	Unconfirmed
C*08:01:14	Unconfirmed	C*08:24	Unconfirmed	C*08:72:02	Confirmed	C*08:122	Unconfirmed
C*08:01:15	Unconfirmed	C*08:25	Unconfirmed	C*08:73	Confirmed	C*08:123	Unconfirmed
C*08:01:16	Unconfirmed	C*08:26N	Unconfirmed	C*08:74	Confirmed	C*08:124	Unconfirmed
C*08:01:17	Unconfirmed	C*08:27	Confirmed	C*08:75	Unconfirmed	C*08:125	Unconfirmed
C*08:01:18	Unconfirmed	C*08:28	Confirmed	C*08:76	Unconfirmed	C*08:126	Unconfirmed
C*08:01:19	Unconfirmed	C*08:29	Confirmed	C*08:77	Unconfirmed	C*08:127N	Unconfirmed
C*08:02:01:01	Confirmed	C*08:30	Confirmed	C*08:78	Unconfirmed	C*08:128	Unconfirmed
C*08:02:01:02	Confirmed	C*08:31	Unconfirmed	C*08:79	Unconfirmed	C*08:129N	Unconfirmed
C*08:02:02	Confirmed	C*08:32	Confirmed	C*08:80	Unconfirmed	C*08:130N	Unconfirmed
C*08:02:03	Unconfirmed	C*08:33:01	Unconfirmed	C*08:81	Unconfirmed	C*08:131	Unconfirmed
C*08:02:04	Confirmed	C*08:33:02	Unconfirmed	C*08:82	Unconfirmed	C*08:132	Unconfirmed
C*08:02:05	Unconfirmed	C*08:33:03	Unconfirmed	C*08:83	Unconfirmed	C*08:133	Unconfirmed
C*08:02:06	Unconfirmed	C*08:34	Confirmed	C*08:84	Unconfirmed	C*08:134	Unconfirmed
C*08:02:07	Confirmed	C*08:35	Unconfirmed	C*08:85	Unconfirmed	C*08:135	Unconfirmed
C*08:02:08	Confirmed	C*08:36N	Unconfirmed	C*08:86	Unconfirmed	C*08:136	Unconfirmed
C*08:02:09	Confirmed	C*08:37	Confirmed	C*08:87	Unconfirmed	C*08:137	Unconfirmed
C*08:02:10	Confirmed	C*08:38	Unconfirmed	C*08:88N	Unconfirmed	C*08:138	Unconfirmed
C*08:02:11	Confirmed	C*08:39	Unconfirmed	C*08:89N	Unconfirmed	C*08:139	Unconfirmed
C*08:02:12	Confirmed	C*08:40	Unconfirmed	C*08:90	Confirmed	C*08:140	Unconfirmed
C*08:02:13	Unconfirmed	C*08:41	Confirmed	C*08:91	Unconfirmed	C*08:141Q	Unconfirmed
C*08:02:14	Unconfirmed	C*08:42	Unconfirmed	C*08:92	Confirmed	C*08:142	Unconfirmed
C*08:03:01	Confirmed	C*08:43	Confirmed	C*08:93	Unconfirmed	C*08:143	Unconfirmed
C*08:03:02	Unconfirmed	C*08:44	Unconfirmed	C*08:94	Confirmed		
C*08:03:03	Unconfirmed	C*08:45	Unconfirmed	C*08:95	Confirmed		
C*08:03:04	Unconfirmed	C*08:46	Unconfirmed	C*08:96	Unconfirmed		
C*08:04:01	Confirmed	C*08:47	Confirmed	C*08:97	Unconfirmed		
C*08:04:02	Unconfirmed	C*08:48	Unconfirmed	C*08:98	Unconfirmed		
C*08:04:03	Unconfirmed	C*08:49	Unconfirmed	C*08:99	Unconfirmed		
C*08:05	Confirmed	C*08:50	Unconfirmed	C*08:100	Unconfirmed		
C*08:06	Confirmed	C*08:51	Unconfirmed	C*08:101	Unconfirmed		
C*08:07	Unconfirmed	C*08:52N	Unconfirmed	C*08:102	Unconfirmed		
C*08:08:01	Unconfirmed	C*08:53	Confirmed	C*08:103	Confirmed		
C*08:08:02	Unconfirmed	C*08:54	Unconfirmed	C*08:104	Unconfirmed		
C*08:09	Unconfirmed	C*08:55N	Unconfirmed	C*08:105	Unconfirmed		
C*08:10	Confirmed	C*08:56	Confirmed	C*08:106	Unconfirmed		
C*08:11	Confirmed	C*08:57	Unconfirmed	C*08:107	Confirmed		
C*08:12	Confirmed	C*08:58	Unconfirmed	C*08:108	Unconfirmed		

¹Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2016-October-14, release 3.26.0, www.ebi.ac.uk/imgt/hla.

RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in HLA-C*08 homo- and heterozygotes is available upon request.



101.623-12 – including *Taq* pol., IFU-01
101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information
SPECIFICITY TABLE

HLA-C*08 SSP subtyping

Specificities and sizes of the PCR products of the 40+1 primer mixes used for
HLA-C*08 SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA-C*08 alleles ³	Other amplified HLA Class I alleles ⁴
1	250 bp	800 bp	*08:01:01-08:01:19, 08:03:01-08:04:03, 08:06, 08:08:01-08:11, 08:13- 08:14, 08:16:01-08:16:02, 08:20-08:22, 08:24, 08:26N, 08:36N, 08:38-08:42, 08:44, 08:46, 08:50, 08:54, 08:56- 08:61, 08:65-08:66, 08:72:01-08:72:02, 08:78- 08:89N, 08:91, 08:93, 08:95- 08:99, 08:101-08:102, 08:104-08:106, 08:109, 08:113, 08:117, 08:119, 08:121N-08:122, 08:124, 08:127N-08:131, 08:133, 08:135-08:139, 08:141Q, 08:143	*01:22, 01:35, 02:03, 02:16:01- 02:16:02, 02:18, 04:04:01-04:04:02, 04:06, 04:13, 04:34, 04:58, 04:122, 04:160, 04:178, 04:212, 05:11, 05:17, 05:27, 05:68, 05:79, 05:115, 05:134, 06:04:01-06:04:02, 06:118, 06:153, 12:14:01-12:14:02, 12:18:01- 12:18:02, 12:20, 12:83, 12:169, 12:175, 12:181, 14:06, 14:15, 14:53, 14:77, 15:02:01:01-15:07, 15:09- 15:13, 15:15-15:19, 15:21-15:24, 15:26-15:50, 15:52-15:73, 15:76- 15:83, 15:85-15:101, 15:103-15:133, 16:35, 16:40, 16:48, 17:01:01:02- 17:16, 17:18-17:34, B*58:02:01
2 ⁵	115 bp	1070 bp	*08:01:01-08:01:19, 08:03:01-08:03:04, 08:06, 08:08:01-08:11, 08:14, 08:16:01-08:16:02, 08:20- 08:22, 08:24, 08:26N, 08:36N, 08:38, 08:40-08:42, 08:44, 08:46, 08:50, 08:56, 08:58-08:61, 08:78-08:89N, 08:91, 08:95-08:99, 08:101- 08:102, 08:105-08:106, 08:109, 08:117-08:119, 08:121N-08:122, 08:124, 08:127N-08:131, 08:133, 08:136-08:137, 08:141Q, 08:143	*05:79
3 ⁵	115 bp	800 bp	*08:02:01:01-08:02:14, 08:04:01-08:05, 08:07, 08:12-08:13, 08:17-08:19, 08:23, 08:25, 08:27-08:35, 08:37, 08:43, 08:45, 08:48- 08:49, 08:52N-08:55N, 08:62, 08:66-08:71, 08:73- 08:76, 08:90, 08:92-08:94, 08:100, 08:103-08:104, 08:107-08:108, 08:110- 08:116, 08:120, 08:123, 08:125-08:126, 08:132, 08:134, 08:138-08:140, 08:142	*03:251, 03:314, 04:120, 05:01:01:01-05:01:34, 05:03-05:08, 05:10-05:11, 05:13-05:16, 05:18:01- 05:51Q, 05:53-05:61, 05:63-05:67, 05:69-05:75, 05:77-05:78:02, 05:80- 05:87, 05:89-05:114, 05:116, 05:118- 05:132, 05:135-05:142, 05:144, 06:129, 07:41, 07:447, 15:130, B*14:32, B*15:337

101.623-12 – including *Taq* pol., IFU-01
101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

4 ^{5,7}	110 bp	1070 bp	*08:03:01-08:03:04, 08:06, 08:14, 08:38, 08:40, 08:61, 08:101, 08:117	*05:79
5	160 bp	1070 bp	*08:05, 08:15:01-08:15:02, 08:21, 08:51, 08:73, 08:137	*01:13, 02:51, 03:87:01-03:87:02, 04:129, 04:223:01-04:223:02, 05:09:01-05:09:03, 05:17, 05:42, 05:46, 05:52, 06:67, 07:101, 07:130, 07:148, 07:161, 12:127, 12:144, 12:185, 16:27, 17:05, B*15:33, B*15:248
6 ⁵	65 bp	800 bp	*08:102	*07:06, 07:18-07:19, 07:330:02, 07:517
	100 bp		*08:14, 08:80, 08:103	*01:02:34, 01:21, 02:42, 02:107, 04:140, 04:166, 04:220, 05:98, 06:05, 07:02:09, 12:16, 12:147, 15:63, 15:113, 16:80, B*67:02
	270 bp		*08:06	*06:161, 16:33
	310 bp		*08:23	
7 ⁵	100 bp	1070 bp	*08:07, 08:47, 08:104	*05:23, 05:62, 05:134, 05:143, 07:01:48, 07:02:35, B*48:04:02
	150 bp		*08:41, 08:115, 08:138	*03:87:01, 03:267, 05:27, 05:39, B*15:01:03
	230 bp		*08:87	
8	240 bp	1070 bp	*08:112	
9	140 bp	1070 bp	*08:88N	
	375 bp		*08:24, 08:75	*02:83, 16:90
	505 bp		*08:10	*05:79
10 ⁵	110 bp	800 bp	*08:09	
	140 bp		*08:17	
11 ⁶	185 bp	800 bp	*08:128	*03:206, 03:212, 04:84
	225 bp		*08:09, 08:11, 08:59, 08:113	*05:04:01-05:04:02, 05:103:01-05:103:02, 05:135, 06:129, 07:68, 07:260:01-07:260:02, 07:302, B*15:337, B*18:83, B*58:76
	255 bp		*08:86	
	280 bp		*08:12	*05:16, 05:85, 05:107, 06:129, 07:364, B*14:32
12	165 bp	800 bp	*08:01:01-08:09, 08:11-08:12, 08:14-08:15:02, 08:17, 08:19-08:24, 08:26N-08:54, 08:56-08:63, 08:65-08:93, 08:95-08:143	*01:43, 02:87, 03:280, 07:101, 07:148, 07:161, 12:127
13 ⁵	105 bp	800 bp	*08:02:01:01-08:02:14, 08:05, 08:07, 08:12, 08:17-08:19, 08:23, 08:25, 08:28, 08:30, 08:32-08:35, 08:37, 08:43, 08:45, 08:47-08:48, 08:52N-08:53, 08:55N, 08:62-08:63, 08:67-08:71, 08:73-08:77, 08:90, 08:92, 08:94, 08:100, 08:103, 08:107-08:108, 08:110-08:112, 08:114-08:116, 08:118, 08:120, 08:123, 08:125-08:126, 08:132, 08:134, 08:140	*03:251, 04:120, 05:01:01:01-05:01:34, 05:03-05:07N, 05:10, 05:12-05:16, 05:18:01-05:26, 05:28-05:51Q, 05:53-05:61, 05:63-05:67, 05:69, 05:71-05:78:02, 05:80-05:88, 05:90-05:105, 05:107-05:111, 05:113N-05:114, 05:116-05:132, 05:135-05:142, 05:144, 07:41

101.623-12 – including *Taq* pol., IFU-01
101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

14	130 bp	1070 bp	*08:90	*03:155, 03:282, 07:413, 07:422, 12:149, B*35:252, B*39:114
	160 bp		*08:18, 08:95	
	280 bp		*08:08:01-08:08:02	
15⁶	265 bp	1070 bp	*08:13, 08:16:01-08:16:02, 08:25, 08:94	*05:29:01-05:29:02
16⁷	545 bp	1070 bp	*08:22, 08:56	*01:85, 15:29, 15:87
17	375 bp	1070 bp	*08:05, 08:21, 08:25, 08:137	*05:42 ^w , 05:46
	430 bp		*08:28, 08:137	*05:25, 05:42
18⁵	80 bp	1070 bp	*08:31	*05:105
	200 bp		*08:26N, 08:92	
19⁵	110 bp	800 bp	*08:27, 08:29-08:31	*05:08, 05:89, 05:106:01-05:106:02, 06:129, 07:447
	250 bp		*08:32	
20⁵	105 bp	1070 bp	*08:35, 08:43, 08:54	*05:44:01, B*15:298
21⁶	195 bp	1070 bp	*08:01:01-08:01:19, 08:03:01-08:03:04, 08:06, 08:08:01-08:11, 08:14, 08:16:01-08:16:02, 08:20- 08:22, 08:24, 08:26N-08:27, 08:33:02-08:33:03, 08:35- 08:36N, 08:38-08:42, 08:44, 08:46, 08:50, 08:54, 08:56, 08:58-08:61, 08:65-08:66, 08:72:01-08:72:02, 08:78- 08:89N, 08:91, 08:95-08:99, 08:101-08:102, 08:105- 08:106, 08:109, 08:117- 08:119, 08:121N-08:122, 08:124, 08:127N-08:131, 08:133, 08:135-08:138, 08:141Q, 08:143	*01:02:06, 01:04, 01:21, 01:97, 02:02:05, 02:02:13, 02:05:01, 02:06:01, 02:10:01:01-02:10:02, 02:12, 02:14:01-02:14:02, 02:16:01, 02:17, 02:27:02, 02:33, 02:40:02, 02:55:02, 02:58, 02:73, 02:76, 02:89, 02:94-02:95, 02:109-02:110, 02:125, 04:01:01:01-04:01:06, 04:01:09- 04:01:76, 04:01:79-04:01:81, 04:03:01-04:20, 04:23-04:159, 04:161-04:162, 04:164-04:222, 04:224-04:240, 04:242-04:257, 05:12, 05:18:01, 05:103:02, 05:106:02, 06:02:01:01-06:02:01:03, 06:02:03-06:02:26, 06:02:28-06:15, 06:17-06:40, 06:42:01-06:61, 06:63- 06:91, 06:93-06:111, 06:113-06:196, 12:02:01-12:03:15, 12:03:18- 12:03:26, 12:03:28-12:03:29, 12:03:31-12:13, 12:14:02-12:31, 12:33-12:143, 12:145-12:180, 12:182-12:184, 12:186-12:200, 14:02:01:01-14:02:04, 14:02:06- 14:16, 14:18-14:81, 15:02:01:01- 15:02:04, 15:02:06-15:02:12, 15:02:14-15:05:05, 15:05:07- 15:06:02, 15:07-15:13, 15:15-15:19, 15:21-15:64, 15:66-15:101, 15:103- 15:133, 16:01:01:01-16:01:20, 16:01:22-16:02:02, 16:02:04- 16:02:13, 16:04:01, 16:04:03- 16:04:04, 16:06-16:26, 16:28-16:99, 16:101, 17:01:01:02-17:01:10, 17:01:12-17:05, 17:07-17:33, 18:01- 18:10
22⁵	80 bp	1070 bp	*08:41, 08:115, 08:138	*03:314, 05:27, 05:39, B*15:337, B*44:148
	155 bp		*08:33:01	*05:18:02-05:18:03, 05:103:01, 05:107, 05:115, 05:134, 07:04:01:01- 07:04:10, 07:11-07:12, 07:63, 07:68, 07:101, 07:139, 07:142, 07:181,

101.623-12 – including *Taq* pol., IFU-01
101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

				07:199:01-07:199:02, 07:260:01-07:260:02, 07:272, 07:302, 07:323-07:324, 07:328-07:329N, 07:336, 07:338, 07:354-07:355, 07:357-07:358, 07:361, 07:364-07:365, 07:378, 07:394-07:395, 07:403, 07:406, 07:420, 07:426, 07:428, 07:459, 07:466-07:467, 07:480, 07:487, 07:501, 07:523, 07:534-07:535, 07:552, 07:562-07:563, B*14:32, B*18:83, B*44:148, B*58:76
23⁵	90 bp	1070 bp	*08:36N, 08:69	*03:174, 07:229, 07:387, 12:131, 14:39, 16:42, 16:56, B*07:243, B*08:98, B*35:202
	140 bp		*08:92, 08:95	*03:155, B*35:252, B*39:114
	205 bp		*08:70Q	
	250 bp		*08:74, 08:78	*01:125, 03:236, 04:106, 07:293, 07:519, B*18:64, B*35:183, B*40:138
24⁵	105 bp	1070 bp	*08:56, 08:89N	*04:179
	150 bp		*08:37, 08:53, 08:74	*02:14:01-02:14:02, 02:107, 04:42:01-04:42:02, 04:220, 04:239, 05:43, 06:05, 07:02:09, 12:16, 12:147, 15:23, 15:63, 16:21, 16:80
25⁵	115 bp	1070 bp	*08:39	*05:12, 07:487, A*29:10:01-29:10:02, B*18:83, B*44:148, B*58:76
	225 bp		*08:09, 08:11, 08:59, 08:113	*05:04:01-05:04:02, 05:103:01-05:103:02, 05:135, 06:129, 07:68, 07:260:01-07:260:02, 07:302, B*15:337, B*18:83, B*58:76
	265 bp		*08:62, 08:82	*03:251, 03:314, 05:05:01-05:05:02, 05:135, A*02:425, A*02:519, A*29:10:01-29:10:02, A*68:69, B*14:32, B*15:337, B*18:83, B*44:148
	290 bp		*08:34	
26⁵	100 bp	1070 bp	*08:14, 08:80, 08:103	*01:02:34, 01:21, 02:42, 02:107, 04:140, 04:166, 04:220, 05:98, 06:05, 07:02:09, 12:16, 12:147, 15:63, 15:113, 16:80, B*67:02
27⁵	125 bp	1070 bp	*08:19, 08:101, 08:143	*04:223:01, 05:64:01-05:64:02
	265 bp		*08:55N	*05:92N
28	155 bp	1070 bp	*08:53	
	185 bp		*08:01:07, 08:02:07, 08:33:02	*03:251, 03:314, 04:120
	290 bp		*08:34	
29	185 bp	1070 bp	*08:128	*03:206, 03:212, 04:84
	210 bp		*08:38, 08:52N	
30⁵	65 bp	1070 bp	*08:99	
	270 bp		*08:110	
	405 bp		*08:28, 08:137	*04:223:01, 05:25, 05:42, 07:01:48, 07:02:35, 07:41, A*01:01:06
	470 bp		*08:20, 08:40	*03:171, 03:211:01, 04:144, 05:93, 06:73, 12:109

101.623-12 – including *Taq* pol., IFU-01
101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

31	500 bp	1070 bp	*08:02:06, 08:19, 08:62	*04:129, 05:01:20, 05:64:01, A*32:72
32	285 bp	1070 bp	*08:44, 08:61, 08:82, 08:126	*03:251, 03:314, 05:10, 15:130, B*44:148, B*58:76
33	155 bp	1070 bp	*08:15:01-08:15:02, 08:51	*01:13, 02:51, 03:87:01-03:87:02, 04:223:01-04:223:02, 05:09:01- 05:09:03, 05:17, 05:52, 07:130, 12:144, 12:185, 16:27, B*15:33, B*15:248
34	215 bp	1070 bp	*08:01:01-08:09, 08:11- 08:63, 08:65-08:72:02, 08:74-08:143	*01:02:01-01:02:40, 01:03-01:13, 01:15-01:18, 01:20-01:58, 01:60, 01:63:01-01:94, 01:96-01:117N, 01:119-01:126, 01:128-01:130, 02:12 ^w , 02:27:01 ^w -02:27:02 ^w , 02:87, 02:115 ^w , 02:126 ^w , 03:03:12, 03:03:15, 03:04:49, 03:11:01, 03:18:01, 03:37:02, 03:39, 03:64:02, 03:94, 03:99, 03:308 ^w , 06:11, 06:122, 06:124, 07:01:01:01-07:01:22, 07:01:24-07:01:40, 07:01:42- 07:02:10, 07:02:12-07:02:32, 07:02:34-07:02:77, 07:04:01:01- 07:04:04, 07:04:06-07:06, 07:08, 07:10-07:19, 07:21-07:33N, 07:35, 07:37-07:48, 07:50-07:58, 07:60- 07:63, 07:65-07:75, 07:77-07:87, 07:89-07:95, 07:96:02-07:123, 07:125-07:126, 07:128-07:154, 07:156-07:172:01, 07:173-07:209, 07:211-07:226, 07:228-07:237, 07:239-07:246:02, 07:248-07:262, 07:264N-07:294, 07:296-07:314:02, 07:316-07:326, 07:329N-07:354, 07:356, 07:358-07:376, 07:379- 07:389, 07:391-07:401, 07:404- 07:405, 07:407-07:437N, 07:439- 07:542, 07:544-07:547, 07:548 ^w , 07:549-07:560, 07:561 ^w , 07:562- 07:563, 12:02:01-12:03:12, 12:03:14- 12:03:24, 12:03:26-12:03:40, 12:06, 12:08, 12:10:01-12:11, 12:13-12:20, 12:22-12:32, 12:34-12:40, 12:42Q- 12:53, 12:56-12:59, 12:61-12:137, 12:139-12:145, 12:147-12:187, 12:189-12:200, 15:07, 15:21, 15:25, 15:116, 16:01:01:01-16:01:22, 16:04:01, 16:04:03-16:04:04, 16:06- 16:08, 16:10-16:11, 16:13-16:18, 16:20-16:24, 16:26-16:33, 16:34 ^w , 16:35-16:38, 16:40-16:45, 16:49- 16:56, 16:58-16:59, 16:61-16:62, 16:64-16:68, 16:71-16:73, 16:75- 16:76, 16:78-16:83, 16:86-16:87, 16:92-16:98, 17:22
35⁵	115 bp	1070 bp	*08:72:01-08:72:02	*03:230, 03:234, 12:169, B*15:88, B*15:200
36⁵	115 bp	1070 bp	*08:121N	B*15:246N

101.623-12 – including *Taq pol.*, IFU-01
101.623-12u – without *Taq pol.*, IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

37	205 bp 265 bp	1070 bp	*08:127N *08:141Q	
38	205 bp 265 bp	1070 bp	*08:129N *08:141Q	
39	350 bp	1070 bp	*08:130N	
40⁵	125 bp 200 bp	1070 bp	*08:42 *08:107	*04:229
41⁸	-	-	Negative Control	

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-C*08 SSP subtypings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

³For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

⁴Due to the sharing of sequence motifs between HLA-C alleles non-HLA-C*08 alleles will be amplified by primer mixes 1 to 7, 9, 11 to 35 and 40 amplify non-HLA-C*08 alleles. In addition, a few HLA-A and HLA-B alleles will be amplified by primer mixes 1, 3, 5 to 7, 11, 14, 20, 22, 23, 25, 26, 30 to 33, 35 and 36.

⁵HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

⁶Primer mixes 11, 15 and 21 may have tendencies of unspecific amplifications.

⁷Primer mixes 4 and 16 may give rise to a lower yield of HLA-specific PCR product than the other HLA-C*08 primer mixes.

⁸Primer mix 41 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 430 base pairs.

'w', might be weakly amplified.

101.623-12 – including *Taq* pol., IFU-01
101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information
PRIMER SPECIFICATION

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec. PCR product	250	115	115	110	160	65	100	240	140	110	185	165
						100	150		375	140	225	
						270	230		505		255	
						310					280	
Length of int. pos. control ¹	800	1070	800	1070	1070	800	1070	1070	1070	800	800	800
5'-primer(s) ²	2 nd I	527	527	527	176	142	453	404	312	176	361	176
	5'-CCA 3'	5'-TAC 3'	5'-TgA 3'	5'-TAC 3'	5'-gCA 3'	5'-TCT 3'	5'-AAT 3'	5'-CCA 3'	5'-AAA 3'	5'-gCA 3'	5'-AgT 3'	5'-gCA 3'
					485	2 nd I	658		429	527	419	
					5'-CAA 3'	5'-CCA 3'	5'-CTA 3'		5'-Ag 3'	5'-TAC 3'	5'-gTC 3'	
						1018			736		634	
						5'-gTg 3'			5'-gCA 3'		5'-CAA 3'	
									757		704	
									5'-CCA 3'		5'-TgT 3'	
3'-primer(s) ³	539	601	601	595	289	201	512	601	526	277	601	302
	5'-TCA 3'	5'-CTT 3'	5'-CTT 3'	5'-CCT 3'	5'-AgC 3'	5'-CTT 3'	5'-CCA 3'	5'-CTT 3'	5'-CgT 3'	5'-gCA 3'	5'-CTT 3'	5'-ggC 3'
					289	559	560		956	598	846	
					5'-AgC 3'	5'-CgC 3'	5'-ACA 3'		5'-CAg 3'	5'-CTC 3'	5'-CAC 3'	
					299	599	846					
					5'-TCT 3'	5'-TCC 3'	5'-CAC 3'					
					601	1043						
					5'-CTC 3'	5'-CAA 3'						
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec. PCR product	105	130	265	545	375	80	110	105	195	80	90	105
		160			430	200	250			155	140	150
		280									205	
											250	
Length of int. pos. control ¹	800	1070	1070	1070	1070	1070	800	1070	1070	1070	1070	1070
5'-primer(s) ²	539	173	1 st I	972	1 st I	441	391	527	2 nd I	486	85	85
	5'-gCg 3'	5'-CgC 3'	5'-CgA 3'	5'-CTA 3'	5'-CgA 3'	5'-TAG 3'	5'-ACT 3'	5'-TgA 3'	5'-CCA 3'	5'-ACC 3'	5'-CCg 3'	5'-CCg 3'
		194				443	520			560	194	88
		5'-CgT 3'				5'-CAA 3'	5'-CgC 3'			5'-CCT 3'	5'-CgT 3'	5'-Tgg 3'
		215				560	539				246	97
		5'-gCA 3'				5'-CgA 3'	5'-gTg 3'				5'-CAg 3'	5'-TCg 3'
		363									257	134
		5'-AgC 3'									5'-CCA 3'	5'-CCg 3'
											374	527
											5'-CTA 3'	5'-TAC 3'
											443	
											5'-CAA 3'	
											3 rd I	
											5'-Cgg 3'	
3'-primer(s) ³	601	302	175	1034	289	601	601	584	485	601	302	201
	5'-CTT 3'	5'-ggC 3'	5'-CCg 3'	5'-AgT 3'	5'-AgC 3'	5'-CTT 3'	5'-CTT 3'	5'-ggC 3'	5'-CCg 3'	5'-CTT 3'	5'-ggC 3'	5'-CTT 3'
		601	175		341			595			538	587
		5'-CTT 3'	5'-CCT 3'		5'-CgT 3'			5'-CCT 3'			5'-CCg 3'	5'-CCg 3'
											787	
											5'-TCT 3'	
Well No.	13	14	15	16	17	18	19	20	21	22	23	24

101.623-12 – including *Taq* pol., IFU-01

101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

Well No.	25	26	27	28	29	30	31	32	33	34	35	36
Length of spec.	115	100	125	155	185	65	500	285	155	215	115	115
PCR product	225		265	185	210	270						
	265			290		405						
	290					470						
Length of int. pos. control ¹	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070
5'-primer(s) ²	351	142	1 st I	88	368	341	176	355	485	126	527	268
	5'-CAA 3'	5'-TCT 3'	5'-CgA 3'	5'-Tgg 3'	5'-gTC 3'	5'-ggA 3'	5'-gCA 3'	5'-TCA 3'	5'-CAA 3'	5'-ggA 3'	5'-TAC 3'	5'-gA 3'
	379		368	351	679	652						
	5'-ACg 3'		5'-gTT 3'	5'-CAA 3'	5'-g.T 3'	5'-CCA 3'						
	419			459	704	851						
	5'-gTC 3'			5'-gAT 3'	5'-TgT 3'	5'-CCT 3'						
	527					934						
	5'-TgT 3'					5'-TCA 3'						
3'-primer(s) ³	601	201	175	201	526	453	387	601	601	299	601	341
	5'-CTT 3'	5'-CTT 3'	5'-CTA 3'	5'-CTT 3'	5'-CgT 3'	5'-TCA 3'	5'-TCC 3'	5'-CTT 3'	5'-CTC 3'	5'-TCA 3'	5'-CTC 3'	5'-Cgg 3'
			453	601	846	956						
			5'-TCA 3'	5'-CTT 3'	5'-CAC 3'	5'-CAg 3'						
Well No.	25	26	27	28	29	30	31	32	33	34	35	36

Well No.	37	38	39	40
Length of spec.	205	205	350	125
PCR product	265	265		200
Length of int. pos. control ¹	1070	1070	1070	1070
5'-primer(s) ²	375	375	28	2 nd I
	5'-Tgg 3'	5'-Tgg 3'	5'-TCA 3'	5'-CCA 3'
	437	438		
	5'-ggA 3'	5'-gAT 3'		
3'-primer(s) ³	601	601	208	412
	5'-CTT 3'	5'-CTT 3'	5'-CTA 3'	5'-CTT 3'
				487
				5'-Cgg 3'
Well No.	37	38	39	40

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

²The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.623-12 – including *Taq* pol., IFU-01
 101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
 “Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-C*08 SSP primer set ³																				
				Well ²																
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
				Prod. No.:	201554301	201554302	201554303	201554304	201779005	201554306	201554307	201554308	201554309	201554310	201779011	201554312	201554313	201554314	201554315	201554316
	IHWC cell line ¹		C*																	
1	9001 SA		*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707		*07:01	*15:05	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324		*12:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373		*03:04	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	9009 KAS011		*06:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM		*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL		*05:01		-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9007 DEM		*04:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT		*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB		*06:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA		*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007		*02:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540		*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367		*01:02	*07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16		*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA		*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL		*01:02	*15:02	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9		*08:02		-	-	+	-	-	-	-	-	-	-	+	+	-	-	-	-
26	9285 WT49		*07:18		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007		*07:04	*15:29	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
28	9320 BEL5GB		*05:01	*16:01	-	-	+	-	-	-	-	-	-	-	-	+	-	-	-	-
29	9050 MOU		*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH		*17:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF		*05:01		-	-	+	-	-	-	-	-	-	-	-	+	-	-	-	-
32	9297 HAG		*17:03		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO		*05:01		-	-	+	-	-	-	-	-	-	-	-	+	-	-	-	-
36	9024 KT17		*03:03	*04:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL		*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML		*02:02	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199		*01:02	*06:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301		*08:02		-	-	+	-	-	-	-	-	-	-	+	+	-	-	-	-
42	9066 TAB089		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526		*01:02	*08:01	+	+	-	-	-	-	-	-	-	-	+	-	-	-	-	-
44	9057 TEM		*12:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO		*06:02	*17:01	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO		*07:04	*15:02	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND		*04:01	*16:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-



101.623-12 – including *Taq* pol., IFU-01
 101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
 “Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

CELL LINE VALIDATION SHEET																			
HLA-C*08 SSP primer set ³																			
				Well ²															
				17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32
				Prod. No.:															
				201554317	201554318	201554319	201554320	201554321	201554322	201554323	201554324	201554325	201779026	201554327	201779028	201779029	201554330	201554331	201779032
IHC cell line ¹		C*																	
1	9001	SA	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280	LK707	*07:01	*15:05	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
3	9011	E4181324	*12:02		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
4	9275	GU373	*03:04	*04:01	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
5	9009	KAS011	*06:02		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
6	9353	SM	*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020	QBL	*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9007	DEM	*04:01		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
9	9026	YAR	*12:03		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
10	9107	LKT3	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051	PITOUT	*16:01		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
12	9052	DBB	*06:02		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
13	9004	JESTHOM	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071	OLGA	*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075	DKB	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037	SWEIG007	*02:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282	CTM3953540	*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257	32367	*01:02	*07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038	BM16	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059	SLE005	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064	AMALA	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056	KOSE	*12:03		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
23	9124	IHL	*01:02	*15:02	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
24	9035	JBUSH	*12:03		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
25	9049	IBW9	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285	WT49	*07:18		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191	CH1007	*07:04	*15:29	-	-	-	-	+	+	-	-	-	-	-	-	-	-	
28	9320	BEL5GB	*05:01	*16:01	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
29	9050	MOU	*16:01		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
30	9021	RSH	*17:01		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
31	9019	DUCAF	*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297	HAG	*17:03		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
33	9098	MT14B	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104	DHIF	*12:03		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
35	9302	SSTO	*05:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024	KT17	*03:03	*04:01	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
37	9065	HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099	LZL	*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315	CML	*02:02	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
40	9134	WHONP199	*01:02	*06:02	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
41	9055	H0301	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066	TAB089	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076	T7526	*01:02	*08:01	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
44	9057	TEM	*12:03		-	-	-	-	+	-	-	-	-	-	-	-	-	-	
45	9239	SHJO	*06:02	*17:01	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
46	9013	SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045	TUBO	*07:04	*15:02	-	-	-	-	+	+	-	-	-	-	-	-	-	-	
48	9303	TER-ND	*04:01	*16:01	-	-	-	-	+	-	-	-	-	-	-	-	-	-	

101.623-12 – including *Taq* pol., IFU-01
 101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
 “Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

CELL LINE VALIDATION SHEET												
HLA-C*08 SSP primer set ³												
				Well ²								
				33	34	35	36	37	38	39	40	
				Prod. No.:	201779033	201779034	201779035	201779036	201779037	201779038	201779039	201779040
IHC cell line ¹		C*										
1	9001 SA	*07:02		-	+	-	-	-	-	-	-	-
2	9280 LK707	*07:01	*15:05	-	+	-	-	-	-	-	-	-
3	9011 E4181324	*12:02		-	+	-	-	-	-	-	-	-
4	9275 GU373	*03:04	*04:01	-	-	-	-	-	-	-	-	-
5	9009 KAS011	*06:02		-	-	-	-	-	-	-	-	-
6	9353 SM	*03:04	*07:02	-	+	-	-	-	-	-	-	-
7	9020 QBL	*05:01		-	-	-	-	-	-	-	-	-
8	9007 DEM	*04:01		-	-	-	-	-	-	-	-	-
9	9026 YAR	*12:03		-	+	-	-	-	-	-	-	-
10	9107 LKT3	*01:02		-	+	-	-	-	-	-	-	-
11	9051 PITOUT	*16:01		-	+	-	-	-	-	-	-	-
12	9052 DBB	*06:02		-	-	-	-	-	-	-	-	-
13	9004 JESTHOM	*01:02		-	+	-	-	-	-	-	-	-
14	9071 OLGA	*01:02	*03:04	-	+	-	-	-	-	-	-	-
15	9075 DKB	*03:04		-	-	-	-	-	-	-	-	-
16	9037 SWEIG007	*02:02		-	-	-	-	-	-	-	-	-
17	9282 CTM3953540	*03:03	*07:01	-	+	-	-	-	-	-	-	-
18	9257 32367	*01:02	*07:05	-	+	-	-	-	-	-	-	-
19	9038 BM16	*07:01		-	+	-	-	-	-	-	-	-
20	9059 SLE005	*03:04		-	-	-	-	-	-	-	-	-
21	9064 AMALA	*03:03		-	-	-	-	-	-	-	-	-
22	9056 KOSE	*12:03		-	+	-	-	-	-	-	-	-
23	9124 IHL	*01:02	*15:02	-	+	-	-	-	-	-	-	-
24	9035 JBUSH	*12:03		-	+	-	-	-	-	-	-	-
25	9049 IBW9	*08:02		-	+	-	-	-	-	-	-	-
26	9285 WT49	*07:18		-	+	-	-	-	-	-	-	-
27	9191 CH1007	*07:04	*15:29	-	+	-	-	-	-	-	-	-
28	9320 BEL5GB	*05:01	*16:01	-	+	-	-	-	-	-	-	-
29	9050 MOU	*16:01		-	+	-	-	-	-	-	-	-
30	9021 RSH	*17:01		-	-	-	-	-	-	-	-	-
31	9019 DUCAF	*05:01		-	-	-	-	-	-	-	-	-
32	9297 HAG	*17:03		-	-	-	-	-	-	-	-	-
33	9098 MT14B	*03:04		-	-	-	-	-	-	-	-	-
34	9104 DHIF	*12:03		-	+	-	-	-	-	-	-	-
35	9302 SSTO	*05:01		-	-	-	-	-	-	-	-	-
36	9024 KT17	*03:03	*04:01	-	-	-	-	-	-	-	-	-
37	9065 HHKB	*07:02		-	+	-	-	-	-	-	-	-
38	9099 LZL	*03:03		-	-	-	-	-	-	-	-	-
39	9315 CML	*02:02	*07:01	-	+	-	-	-	-	-	-	-
40	9134 WHONP199	*01:02	*06:02	-	+	-	-	-	-	-	-	-
41	9055 H0301	*08:02		-	+	-	-	-	-	-	-	-
42	9066 TAB089	*01:02		-	+	-	-	-	-	-	-	-
43	9076 T7526	*01:02	*08:01	-	+	-	-	-	-	-	-	-
44	9057 TEM	*12:03		-	+	-	-	-	-	-	-	-
45	9239 SHJO	*06:02	*17:01	-	-	-	-	-	-	-	-	-
46	9013 SCHU	*07:02		-	+	-	-	-	-	-	-	-
47	9045 TUBO	*07:04	*15:02	-	+	-	-	-	-	+	-	-
48	9303 TER-ND	*04:01	*16:01	-	+	-	-	-	-	-	-	-



101.623-12 – including *Taq* pol., IFU-01
 101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
 “Instructions for Use” (IFU)

Lot No.: 1F2

Lot-specific information

¹The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

²The C*07:18 allele is amplified by primer mix 6 in the 9285 (WT49) cell line.

³The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 5, 7 to 11, 14, 15, 17 to 19, 23 to 33 and 35 to 40 were available.

The specificity of the primers in primer solutions 5, 7, 9, 11, 14, 15, 17 to 19, 23 to 33 and 35 were tested by adding additional 5'-primers respectively 3'-primers. In primer solution 10, 39 and 40 it was only possible to test the 5'-primers, the 3'-primers were not possible to test.

In primer solution 8 and 36 to 38 it was only possible to test the 3'-primer, the 5'-primers were not possible to test. In primer solution 7, 9, 11, 14, 18, 19, 23 to 25 and 28 to 30 one or more 5'-primers were not possible to test. In primer solutions 6, 24 and 27, one or two 3'-primers were not possible to test.

Additional primers in primer solutions 6, 20 and 22 were tested by separately adding either 5'-primers and/or one or two 3'-primers.

101.623-12 – including *Taq* pol., IFU-01
101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
“Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

101.623-12 – including *Taq* pol., IFU-01
 101.623-12u – without *Taq* pol., IFU-02

Visit www.olerup.com for
 “Instructions for Use” (IFU)

Lot No.: **1F2**

Lot-specific information

ADDRESSES:

Manufacturer:

Olerup SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-717 88 27

Fax: +46-8-717 88 18

E-mail: olerup-se@caredx.com

Web page: <http://www.olerup.com>

Distributed by:

Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00

Fax: +43-1-710 15 00 10

E-mail: olerup-at@caredx.com

Web page: <http://www.olerup.com>

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-OLERUP1

Fax: 610-344-7989

E-mail: olerup-us@caredx.com

Web page: <http://www.olerup.com>

For information on *Olerup* distributors worldwide, contact **Olerup GmbH**.